following an abbreviated submission
triptorelin pamoate 22.5mg (Decapeptyl SR®) is accepted for use within NHS Scotland.
Indication under review:
•Treatment of patients with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration.
•Treatment of metastatic prostate cancer.
This new preparation of triptorelin allows 6-monthly administration (as triptorelin pamoate in a 22.5mg dose). Triptorelin 11.25mg (as acetate) is administered every 3 months and has previously been accepted by SMC. Bioequivalence of the pamoate and acetate salts has been demonstrated and the new preparation is cost neutral.
Note: The indication for triptorelin 11.25mg formulation was reworded in 2007 to achieve consistency Europe-wide and now reads as per the indication for triptorelin 22.5mg.
Download detailed advice52KB (PDF)
- Medicine name:
- triptorelin pamoate (Decapeptyl SR 22.5mg)
- SMC ID:
- Prostate Cancer
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Endocrine system
- Submission type
- Date advice published
- 13 June 2011